CD276 and neoplasm: The m276‐SL‐PBD antibody–drug conjugate (ADC) developed by a research team [27] targeting B7‐H3 has shown strong antitumor effects in mice models of various childhood tumor cell and is a brand‐new pediatric solid tumor therapeutic target.